Relovair (GSK/Theravance)programme is now complete for COPD and Asthma

Glaxo Smith Kline and Theravance, Inc. have announced that the registration programme for Relovair (fluticasone furoate plus vilanterol) is now complete. In addition, results from two studies for the once-daily Relovair (fluticasone furoate "FF"/vilanterol "VI" (FF/VI)) in patients with chronic obstructive pulmonary disease (COPD) and results from a study to evaluate the efficacy and safety of FF and FP (fluticasone propionate) compared to placebo in the treatment of persistent asthma in adults and adolescents were announced. The full results of all these studies will be presented at future scientific meetings.